Pure Financial Advisors LLC Purchases New Shares in HCA Healthcare, Inc. $HCA

Key Points

• Pure Financial Advisors LLC has acquired 644 shares of HCA Healthcare, valued at approximately $247,000, reflecting increasing institutional interest in the company.
• Analysts have provided positive forecasts for HCA Healthcare, with target price adjustments from various firms, including Barclays raising it to $445.00 and Cantor Fitzgerald maintaining an "overweight" rating.
• HCA Healthcare recently announced a quarterly dividend of $0.72 per share, equivalent to an annualized rate of $2.88, indicating a 0.7% yield on its stock.

Pure Financial Advisors LLC bought a new stake in shares of HCA Healthcare, Inc. (NYSE:HCA - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 644 shares of the company's stock, valued at approximately $247,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Childress Capital Advisors LLC acquired a new stake in shares of HCA Healthcare during the second quarter worth approximately $232,000. PBMares Wealth Management LLC acquired a new position in HCA Healthcare during the 2nd quarter worth $209,000. Park Place Capital Corp lifted its position in shares of HCA Healthcare by 2,336.0% during the second quarter. Park Place Capital Corp now owns 1,218 shares of the company's stock worth $474,000 after purchasing an additional 1,168 shares during the last quarter. Capital Investment Advisors LLC acquired a new stake in HCA Healthcare during the second quarter valued at approximately $234,000. Finally, Asio Capital LLC increased its holdings in shares of HCA Healthcare by 0.9% in the 2nd quarter. Asio Capital LLC now owns 17,209 shares of the company's stock valued at $6,593,000 after acquiring an additional 147 shares during the last quarter. 62.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $444.00 target price on shares of HCA Healthcare in a research note on Tuesday, August 26th. Bank of America increased their price objective on shares of HCA Healthcare from $375.00 to $410.00 and gave the stock a "neutral" rating in a research note on Wednesday, September 10th. Barclays upped their target price on HCA Healthcare from $390.00 to $445.00 and gave the company an "overweight" rating in a report on Thursday, September 18th. Truist Financial boosted their price objective on HCA Healthcare from $390.00 to $415.00 and gave the company a "buy" rating in a research report on Wednesday, July 16th. Finally, Robert W. Baird raised their target price on HCA Healthcare from $380.00 to $423.00 and gave the company a "neutral" rating in a research note on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $407.75.

Insider Activity at HCA Healthcare

In other news, EVP Michael S. Cuffe sold 3,836 shares of the firm's stock in a transaction on Monday, September 8th. The stock was sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the completion of the sale, the executive vice president directly owned 31,503 shares of the company's stock, valued at $13,194,716.52. This trade represents a 10.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 1.30% of the company's stock.

HCA Healthcare Price Performance

NYSE HCA opened at $429.52 on Friday. The company's 50 day simple moving average is $397.53 and its 200 day simple moving average is $372.65. The firm has a market capitalization of $100.50 billion, a PE ratio of 18.05, a P/E/G ratio of 1.35 and a beta of 1.40. HCA Healthcare, Inc. has a 12 month low of $289.98 and a 12 month high of $432.36.

HCA Healthcare (NYSE:HCA - Get Free Report) last posted its quarterly earnings data on Friday, July 25th. The company reported $6.84 EPS for the quarter, topping analysts' consensus estimates of $6.20 by $0.64. HCA Healthcare had a negative return on equity of 7,363.11% and a net margin of 8.21%.The company had revenue of $18.61 billion for the quarter, compared to the consensus estimate of $18.49 billion. During the same quarter in the previous year, the business earned $5.50 EPS. The company's quarterly revenue was up 6.4% compared to the same quarter last year. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. Sell-side analysts anticipate that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Tuesday, September 16th were issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date was Tuesday, September 16th. HCA Healthcare's dividend payout ratio (DPR) is presently 12.11%.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.